Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03552471
Recruitment Status : Recruiting
First Posted : June 11, 2018
Last Update Posted : February 25, 2021
Sponsor:
Collaborators:
ImmunoGen, Inc.
Clovis Oncology, Inc.
Information provided by (Responsible Party):
Floor Backes, Ohio State University Comprehensive Cancer Center

Tracking Information
First Submitted Date  ICMJE April 26, 2018
First Posted Date  ICMJE June 11, 2018
Last Update Posted Date February 25, 2021
Actual Study Start Date  ICMJE July 12, 2018
Estimated Primary Completion Date August 29, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 29, 2018)
Recommended phase II dose (RPTD) of mirvetuximab soravtansine and rucaparib camsylate in combination [ Time Frame: At the end of Cycle 1 (each cycle 15 days) ]
based on DLT and toxicity
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 9, 2018)
  • Incidence of adverse effects graded according to CTCAE v. 4.0 [ Time Frame: while on study drug and up to 30 days after (through study treatment completion, an average of 1 year) ]
    Will be evaluated descriptively using frequencies and percentages
  • Objective anti-tumor activity (complete and partial response) of mirvetuximab soravtansine and rucaparib in combination [ Time Frame: Up to 1 year after completion of study treatment ]
    Response rate determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
  • Progression-free survival [ Time Frame: From start of treatment up to 1 year after completion of study treatment ]
    Progression-free survival determined by Kaplan-Meier curves.
Original Secondary Outcome Measures  ICMJE
 (submitted: May 29, 2018)
  • Incidence of adverse effects graded according to CTCAE v. 4.0 [ Time Frame: while on treatment and up to 30 days after ]
    Will be evaluated descriptively using frequencies and percentages
  • Objective anti-tumor activity (complete and partial response) of mirvetuximab soravtansine and rucaparib in combination [ Time Frame: Up to 1 year after completion of study treatment ]
    Response rate determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
  • Progression-free survival [ Time Frame: From start of treatment up to 1 year after completion of study treatment ]
    Progression-free survival determined by Kaplan-Meier curves.
Current Other Pre-specified Outcome Measures
 (submitted: July 13, 2018)
Pharmacokinetics of mirvetuximab soravtansine and rucaparib in combination Cmax trough concentrations [ Time Frame: predose and post dose at selected times ]
Pharmacokinetics determined by analysis of collected blood samples
Original Other Pre-specified Outcome Measures
 (submitted: May 29, 2018)
  • Pharmacokinetics of mirvetuximab soravtansine and rucaparib in combination Cmax trough concentrations [ Time Frame: Pre-dose on days 1 and 8 of course 1; pre-dose and within 60 minutes of infusion completion on day 1 of courses 1-4; and pre-dose and at 1, 2, 4, 6, and (optional) 8 hours post-dose on day 15 of course 1 ]
    Pharmacokinetics determined by analysis of collected blood samples
  • Pharmacokinetics of mirvetuximab soravtansine and rucaparib in combination tmax trough concentrations [ Time Frame: Pre-dose on days 1 and 8 of course 1; pre-dose and within 60 minutes of infusion completion on day 1 of courses 1-4; and pre-dose and at 1, 2, 4, 6, and (optional) 8 hours post-dose on day 15 of course 1 ]
    Pharmacokinetics determined by analysis of collected blood samples
  • Pharmacokinetics of mirvetuximab soravtansine and rucaparib in combination AUC 0 trough concentrations [ Time Frame: Pre-dose on days 1 and 8 of course 1; pre-dose and within 60 minutes of infusion completion on day 1 of courses 1-4; and pre-dose and at 1, 2, 4, 6, and (optional) 8 hours post-dose on day 15 of course 1 ]
    Pharmacokinetics determined by analysis of collected blood samples
 
Descriptive Information
Brief Title  ICMJE Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Official Title  ICMJE Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Brief Summary This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and rucaparib camsylate in treating participants with endometrial, ovarian, fallopian tube or primary peritoneal cancer that has come back. Drugs such as mirvetuximab soravtansine are antibodies linked to a toxic substance and may help find certain tumor cells and kill them without harming normal cells. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving mirvetuximab soravtansine and rucaparib camsylate may work better in treating participants with recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer.
Detailed Description

PRIMARY OBJECTIVES:

I. To determine the recommended phase II dose (RPTD) of combination mirvetuximab soravtansine and rucaparib camsylate (rucaparib) in patients with recurrent endometrial, epithelial ovarian, primary peritoneal, or fallopian tube carcinoma.

SECONDARY OBJECTIVES:

I. To determine the safety and tolerability of combination mirvetuximab soravtansine and rucaparib in study patients.

II. To explore the objective antitumor activity (complete and partial response) of combination mirvetuximab soravtansine and rucaparib as measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria in the study population.

III. To measure the progression free survival. IV. To evaluate the pharmacokinetics of mirvetuximab soravtansine and rucaparib in combination.

EXPLORATORY OBJECTIVES:

I. Explore additional biomarkers of response. II. Explore mutation characteristics and frequency with treatment response. III. Evaluate if companion diagnostics can be optimized by combining loss of heterozygosity (LOH) score and level of folate receptor a (FR-alpha) expression, and possible additional predictors of response.

IV. Explore mechanisms of secondary resistance to treatment.

OUTLINE: This is a dose escalation study.

Participants receive mirvetuximab soravtansine intravenously (IV) on day 1 and rucaparib orally (PO) twice daily (BID) on days 1 through 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, participants are followed up at 30 days and then every 3 months for up to a year.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • BRCA1 Gene Mutation
  • BRCA2 Gene Mutation
  • Folate Receptor Alpha Positive
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Ovarian Carcinoma
  • Recurrent Primary Peritoneal Carcinoma
  • Recurrent Uterine Corpus Carcinoma
  • Recurrent Uterine Serous Carcinoma
  • Recurrent Uterine Carcinosarcoma
  • Platinum Resistant Ovarian Cancer
Intervention  ICMJE
  • Other: Laboratory Biomarker Analysis
    Correlative studies
  • Biological: Mirvetuximab Soravtansine
    Given IV
    Other Names:
    • IMGN853
    • M9346A-sulfo-SPDB-DM4
  • Other: Pharmacokinetic Study
    Correlative studies
    Other Names:
    • PHARMACOKINETIC
    • PK Study
  • Drug: Rucaparib Camsylate
    Given PO
    Other Names:
    • 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt
    • C0-338
    • Rubraca
    • Rucaparib Phosphate
Study Arms  ICMJE Experimental: Treatment (mirvetuximab soravtansine, rucaparib)
Participants receive mirvetuximab soravtansine IV on day 1 and rucaparib PO BID on days 1 through 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Interventions:
  • Other: Laboratory Biomarker Analysis
  • Biological: Mirvetuximab Soravtansine
  • Other: Pharmacokinetic Study
  • Drug: Rucaparib Camsylate
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 29, 2018)
42
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE August 29, 2021
Estimated Primary Completion Date August 29, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed:

    • Recurrent endometrial cancer (all histologies, including carcinosarcoma)
    • Recurrent ovarian, primary peritoneal (female only), or fallopian tube cancer

      • all histologies except low grade serous or clear cell carcinoma unless the patient has a known somatic or germline breast cancer (BRCA) mutation disease that is metastatic and for which standard curative measures do not exist or are no longer effective
  • For the dose escalation portion of the trial, patients with available therapies known to confer clinical benefit (platinum sensitive ovarian cancer) must be excluded
  • For the dose expansion cohort, patients with recurrent endometrial cancer, recurrent BRCA mutated ovarian cancer (except first-recurrence platinum sensitive ovarian cancer), and platinum resistant ovarian cancer are eligible
  • Patients must have confirmation of folate receptor-a (FR-alpha) positivity by immunohistochemistry (IHC) (? 25% of tumor staining at ? 2 + intensity) on archival tissue or recent biopsy.
  • Patients must be willing and able to undergo tissue biopsy for research

    • If tumor tissue obtained from the biopsy is deemed inadequate, and the patient is unwilling or unable to have another biopsy, the patient may be considered for enrollment if archival tumor tissue is provided and deemed of adequate quality; this must occur prior to any treatment with rucaparib or mirvetuximab soravtansine
    • If biopsy is deemed unsafe to attempt or to perform, and if archival tumor tissue is available and deemed of adequate quality, the patient may enroll on trial
    • Biopsy must be of solid tumor tissue; ascites is not acceptable
  • Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)
  • Prior therapy:

    • Patients may have received unlimited prior treatment for the dose escalation part
    • For the expansion cohort patients must have ? 4 prior lines of chemotherapy
    • Hormonal therapy does not count towards total lines of therapy
    • Maintenance therapy is considered part of the preceding regimen if one or more of the same drugs are continued
    • Neoadjuvant and adjuvant chemotherapy are considered one regimen if they are a continuation of the same regimen with interval debulking surgery
  • Prior treatment with folate receptor (FR) targeting investigational agents is allowed for dose escalation provided that such treatment was not discontinued due to adverse events; prior FR-targeting investigational agents are not allowed for patients in the expansion cohort
  • Patients with recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer must have received at least one platinum-based chemotherapy regimen
  • Patients who have received prior taxanes, including weekly taxanes are allowed
  • Patients previously treated with a poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor may be enrolled provided:

    • PARP inhibitor was not the most recent treatment
    • PARP inhibitor treatment was discontinued > 6 months before the first planned dose of rucaparib
  • Time from prior therapy:

    • Systemic anti-neoplastic therapy: five half-lives or four weeks, whichever is shorter (6 weeks for nitrosoureas or mitomycin C)
    • Hormonal therapy is not considered anti-neoplastic therapy
    • Radiotherapy: wide-field radiotherapy (e.g. > 30% of marrow-bearing bones) completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study treatment
  • Eastern cooperative oncology group (ECOG) performance status ? 1 and life expectancy > 12 weeks
  • Leukocytes ? 2,000/mcL
  • Absolute neutrophil count ? 1,500/mcL
  • Platelets ? 100,000/mcL
  • Hemoglobin ? 9.0 g/dL
  • Total bilirubin ? 1.5 x upper limit of normal (ULN) (Patients with documented diagnosis of Gilbert syndrome are eligible if total bilirubin < 3.0 x ULN)
  • Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT)/ alanine aminotransferase (ALT) serum glutamate pyruvate transaminase (SGPT) ? 2.5 ? institutional upper limit of normal
  • Creatinine ? 1.5 x upper limit of normal (ULN) OR creatinine clearance ? 50 mL/min/1.73 m^2 (using Cockroft Gault Formula) for patients with creatinine levels above institutional normal
  • Corrected QT (QTc) interval ? 470 msec on screening electrocardiogram (ECG)
  • Major surgery must have been completed ? 4 weeks prior to starting treatment day 1; patient must be sufficiently recovered and stable from surgery prior to treatment day 1
  • Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; patients must have a negative pregnancy test (urine and/or serum) prior to enrollment
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Patients with available therapies known to confer clinical benefit (platinum sensitive recurrent ovarian cancer) must be excluded from the dose escalation portion
  • For the dose expansion cohort patients with first-recurrence platinum-sensitive ovarian cancer must be excluded
  • Patients who have had chemotherapy or radiotherapy within 4 weeks or five half-lives whichever is shorter (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual drug related toxicities > grade 1) except for alopecia and grade 2 fatigue
  • Patients who are receiving any other investigational agents
  • Primary platinum refractory disease (disease progression on first platinum treatment or recurrence within 3 months of completing first platinum regimen)
  • Patients with clear cell or low grade ovarian cancer unless the patient has a known germline or somatic breast cancer (BRCA) mutation or a mutation in another homologous recombination gene
  • Any known gastrointestinal disorder determined by the investigator that interferes with the absorption of rucaparib
  • Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids; patients with treated brain metastases are eligible as long as they completed prior brain radiation therapy more than 14 days prior to first dose of study therapy, are not experiencing seizures and are not receiving steroids for symptomatic brain metastases (for at least 7 days prior to first dose of study treatment)
  • History of leptomeningeal carcinomatosis
  • Subjects with a known history of uncontrolled seizures
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to rucaparib, mirvetuximab soravtansine or monoclonal antibodies
  • Uncontrolled inter-current illness including, but not limited to:

    • Ongoing or active infection (requiring IV antibiotics within 2 weeks of study enrollment)
    • Symptomatic/uncontrolled congestive heart failure (New York heart association > class II)
    • Unstable angina pectoris
    • Recent myocardial infarction (< 6 months)
    • Uncontrolled cardiac arrhythmia
    • Uncontrolled hypertension (? Common Terminology Criteria for Adverse Events [CTCAE] v4.03 grade 3)
    • Prior history of hypertensive crisis or hypertensive encephalopathy
    • Hemorrhagic or ischemic stroke < 6 months
    • Clinically-significant vascular disease (e.g. aortic aneurysm, or dissecting aneurysm), severe aortic stenosis clinically significant peripheral vascular disease, or ? grade 3 cardiac toxicity following prior chemotherapy
    • Interstitial lung disease (ILD)
    • Active peptic ulcer disease or gastritis interfering with the absorption of rucaparib
    • Active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C
    • Active varicella zoster infection, cytomegalovirus infection, or history of tuberculosis
    • Psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent
  • Active or chronic corneal disorder, including but not limited to the following: Sjogren?s syndrome, Fuchs corneal dystrophy (requiring treatment), history of corneal transplantation, active herpetic keratitis, and also active ocular conditions requiring on-going treatment/monitoring such as wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, presence of papilledema, acquired monocular vision, and any preexisting active conjunctival disease
  • History of neurological conditions that would confound assessment of treatment-emergent neuropathy
  • History of multiple sclerosis or other demyelinating disease and/or Eaton-Lambert syndrome (para-neoplastic syndrome)
  • Previous clinical diagnosis of non-infectious pneumonitis
  • History or evidence of thrombotic disorders within 6 months before first study treatment unless stable on anticoagulation for > 3 months
  • Required used of folate-containing supplements (e.g. folate deficiency)
  • Has a known additional malignancy that is progressing or required active treatment within 3 years of first dose of study treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or other in situ cancers
  • Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with rucaparib and mirvetuximab soravtansine
  • Women who are breastfeeding
  • Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
  • Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: The Ohio State University Comprehensive Cancer Center 1-800-293-5066 OSUCCCClinicaltrials@osumc.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03552471
Other Study ID Numbers  ICMJE OSU-18007
NCI-2018-00438 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Floor Backes, Ohio State University Comprehensive Cancer Center
Study Sponsor  ICMJE Ohio State University Comprehensive Cancer Center
Collaborators  ICMJE
  • ImmunoGen, Inc.
  • Clovis Oncology, Inc.
Investigators  ICMJE
Principal Investigator: Floor Backes, MD Ohio State University Comprehensive Cancer Center
PRS Account Ohio State University Comprehensive Cancer Center
Verification Date February 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP